AbbVie Inc. (NYSE:ABBV) Stock Sees The Needle Move -4.34%

Glen Mclaughlin
October 29, 2017

Abbvie Inc now has $146.55 billion valuation.

A number of large investors have recently added to or reduced their stakes in the business. Acropolis Investment Management LLC purchased a new position in shares of AbbVie during the second quarter valued at approximately $106,000. This is an increase from AbbVie's previous quarterly dividend of $0.57. During the last trade, stock's minimum price has been reached out at $47.48 while the maximum trading price moved at $47.95. Franklin Parlapiano Turner & Welch LLC acquired a new stake in shares of AbbVie during the 1st quarter worth approximately $108,000. It also reduced its holding in Norfolk Southern Co (NYSE:NSC) by 9,515 shares in the quarter, leaving it with 52,799 shares, and cut its stake in General Mills Inc (NYSE:GIS). Barr E S & Company invested in 5,739 shares.

In related news, Chairman Richard A. Gonzalez sold 87,899 shares of the firm's stock in a transaction on Friday, August 4th.

Stock exchanges work according to the invisible hand of supply and demand, which determines the price where stocks are bought and sold. The company has experienced volume of 2,456,629 shares while on average the company has a capacity of trading 1.08M share.

Philippe Jabre increased its stake in Twitter Inc (TWTR) by 7.35% based on its latest 2017Q2 regulatory filing with the SEC. $2.88M worth of AbbVie Inc (NYSE:ABBV) shares were sold by ALBAN CARLOS. The shares were sold at an average price of $70.09, for a total transaction of $1,261,620.00. Outstanding shares refer to a company's stock presently held by all its shareholders, counting share blocks held by institutional shareholders and restricted shares owned by the company's officers and insiders. The disclosure for this sale can be found here. Given the stock's recent action, it seemed like a good time to take a closer look at the company's recent data. Sands Management Ltd Limited Liability Company invested in 25.20 million shares or 0.42% of the stock.

More news: 5 teens charged with murder in MI rock throwing case
More news: Local agencies taking part in DEA's drug take back Saturday
More news: This is now the most powerful passport in the world

ILLEGAL ACTIVITY NOTICE: This piece of content was first published by TrueBlueTribune and is owned by of TrueBlueTribune. If you are accessing this article on another website, it was illegally copied and reposted in violation of United States and global trademark and copyright law.

Analysts on average have given a price target of $92.67 to AbbVie Inc.

Several large investors have recently modified their holdings of ABBV. This indicates a relatively solid earnings per share growth rate of 73.21% over the next few years, which is an optimistic outlook in the near term. BidaskClub cut AbbVie from a strong-buy rating to a buy rating in a research report on Friday, July 28th. Forte Cap Ltd Liability Company Adv reported 15,511 shares stake. Piper Jaffray Companies reaffirmed a buy rating and set a $85.00 price objective on shares of AbbVie in a research report on Thursday, August 3rd. The stock of AbbVie Inc (NYSE:ABBV) has "Hold" rating given on Thursday, July 20 by Credit Suisse. The stock of AbbVie Inc (NYSE:ABBV) earned " rating by Citigroup on Monday, September 28. They are also projecting the Low EPS estimate of $1.37 and the High EPS estimate of $1.58. (NYSE:ABBV) opened at 91.93 on Friday. The stock is trading $84.89 its 50-day moving average by -4.67%. The firm has a market capitalization of $93.80 billion, a price-to-earnings ratio of 15.57 and a beta of 1.50.

AbbVie (NYSE:ABBV) last posted its quarterly earnings results on Friday, October 27th. The average estimate of nine analysts surveyed by Zacks Investment Research was for earnings of $1.39 per share. ABBV generated revenue of $7.49 Billion in the same quarter, one year ago. AbbVie had a return on equity of 164.49% and a net margin of 24.08%. The company's average Piotroski F-Score: 5 during the last 7 years. Stockholders of record on Friday, January 13th will be given a dividend of $0.64 per share. The ex-dividend date of this dividend is Thursday, October 12th. This represents a $2.56 dividend on an annualized basis and a dividend yield of 4.44%. The Return on Investment (ROI) ratio of AbbVie Inc.

The Chicago-based company is also targeting Alzheimer's disease, the women's health space and Hepatitis C. The Firm operates through three divisions: Allergy, which relates to a range of immunotherapy development products for the treatment of allergy; NIOX, which relates to the portfolio of products used to improve asthma diagnosis and management by measuring fractional exhaled nitric oxide, and Respiratory, which relates to the portfolio of asthma and chronic obstructive pulmonary disease product candidates.

Other reports by MaliBehiribAe

Discuss This Article